Different binding and recognition modes of GL479, a dual agonist of Peroxisome Proliferator-Activated Receptor α/γ

Jademilson Celestino dos Santos1, Amanda Bernardes1, Letizia Giampietro2

  • 1Grupo de Biotecnologia Molecular, Instituto de Física de São Carlos, Universidade de São Paulo, São Carlos, SP 13566-590, Brazil.

Insights

Dual Peroxisome Proliferator-Activated Receptor (PPAR) agonists like GL479 show distinct binding modes in PPARα and PPARγ receptors. These structural insights may guide the development of new treatments for insulin resistance and dyslipidemia.

Area of Science:

  • Biochemistry
  • Structural Biology
  • Pharmacology

Background:

  • Peroxisome Proliferator-Activated Receptors (PPARs) are crucial transcription factors regulating glucose and lipid metabolism.
  • PPARγ agonists (TZDs) improve insulin sensitivity, while PPARα ligands (fibrates) reduce triglycerides.
  • GL479 is a synthetic dual PPARα/γ agonist with high affinity for both receptors.

Purpose of the Study:

  • To elucidate the structural basis of GL479's dual agonism by studying its complexes with PPARα and PPARγ.
  • To understand how GL479's distinct binding modes influence its activation of PPARα versus PPARγ.
  • To identify novel regions within the PPAR ligand-binding pocket for future drug design.

Main Methods:

  • X-ray crystallography was used to determine the structures of GL479 in complex with PPARα and PPARγ.
  • Comparative analysis of the ligand-binding pocket occupancy and interactions in both receptor complexes.
  • Assessment of GL479's previously reported partial PPARγ and full PPARα agonist activities.

Main Results:

  • GL479 exhibits different binding modes when complexed with PPARα and PPARγ.
  • In both receptors, GL479 interacts with a tyrosine residue in helix 12, stabilizing the active conformation.
  • GL479 occupies a canonical pocket in PPARα but a novel region in PPARγ.

Conclusions:

  • The distinct structural interactions of GL479 with PPARα and PPARγ explain its differential activation profiles.
  • The findings reveal a previously unexplored region of the PPAR ligand-binding pocket.
  • This structural understanding can inform the design of novel partial and dual PPAR agonists for treating metabolic disorders.

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
961
GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
8.3K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
Transducer Mechanism: G Protein–Coupled Receptors01:30

Transducer Mechanism: G Protein–Coupled Receptors

G Protein–Coupled Receptors (GPCRs) are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to various stimuli. GPCRs regulate critical physiological pathways and are excellent drug targets for treating diseases such as diabetes, cancer, obesity, depression, or Alzheimer's. Nearly 35% of approved drugs implement their therapeutic effects by selectively interacting with specific GPCRs.
GPCRs are also called heptahelical,...
8.2K
G Protein-coupled Receptors01:15

G Protein-coupled Receptors

G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
19.8K